Loading...
Gene expression profiling of patient‐derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts
c‐MYC controls more than 15% of genes responsible for proliferation, differentiation, and cellular metabolism in pancreatic as well as other cancers making this transcription factor a prime target for treating patients. The transcriptome of 55 patient‐derived xenografts show that 30% of them share a...
Na minha lista:
| Udgivet i: | EMBO Mol Med |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5376755/ https://ncbi.nlm.nih.gov/pubmed/28275007 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201606975 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|